CAJ – Credit Suisse rates the stock as Outperform

In a consolidating market, Credit Suisse foresees material upside in both a stand-alone and merger scenario for the company. The broker expects only modest improvement in growth in the second half relative to a weak first half but believes the issues are transient, such as bottlenecks in Victoria.

The broker reviews near-term estimates and forecasts FY20 operating earnings (EBITDA) of $29.7m. Credit Suisse believes Capitol Health can still generate a very healthy earnings growth profile in the outer years despite growing below industry trends of around 6%.

Credit Suisse maintains an Outperform rating and $0.28 target.

Sector: Health Care Equipment & Services.

Target price is $0.28.Current Price is $0.22. Difference: $0.06 – (brackets indicate current price is over target). If CAJ meets the Credit Suisse target it will return approximately 21% (excluding dividends, fees and charges – negative figures indicate an expected loss).

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →